In vivo CAR-T takeaways from EHA call

Research evidence excerpt

In vivo CAR-T takeaways from EHA call

Update

June 16, 2026 05:56 PM GMT

Morgan Stanley & Co. LLCMLegend Biotech Corp | North America Terence C Flynn, Ph.D.

Equity Analyst

In vivo CAR-T takeaways from Terence.Flynn@morganstanley.comHailey Horowitz +1 212 761-2230

Research Associate

Hailey.Horowitz@morganstanley.com +1 212 761-5264

EHA call Chris Yu, J.D., Ph.D.

Chris.L.Yu@morganstanley.com +1 212 761-2535

LEGN hosted a sell-side call to discuss Ph1 data for LB2501 (lentiviral

Connor M Massari

CD19xCD20 in vivo CAR-T) in R/R. NHL recently presented at EHA conference; Equity Analyst

see our take on the abstract HERE. As we previously highlighted we view these Connor.Massari@morganstanley.com +1 212 761-2417

Alexander Yevdokimov, Ph.D.

initial data as encouraging, and we await longer follow-up to get a better sense Research Associate

of durability, which is a key outstanding question (for LEGN and the field in Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Damien H Kerner

general). We expect another update at a major medical meeting in 2H26 - we see Research Associate

IMS (Sept. 23-26), ESMO (Oct. 23-27), and ASH (Dec. 12-15) as potential venues. Damien.H.Kerner@morganstanley.com +1 212 761-3829

Morgan Stanley India Company Private Limited+

With respect to the LEGN2501 Ph1 data at dose level 2 (n=6), ORR was 100% with

Saket Agarwal

CR of 83.3%, and all responses were ongoing at data cutoff (median follow-up of Research Associate

2.2mos); Exhibit 1 . Dose-dependent in vivo CAR-T expansion was observed with no Saket.Agarwal@morganstanley.com +91 22 6995-4012

DLTs, SAEs, or deaths. CRS occurred in 66.7% of patients (all Gr1/2); no ICANS was

Legend Biotech Corp (LEGN.O, LEGN US)

reported. Gr3+ lentiviral vector or CAR-T-related AE's were decreased lymphocyte